key: cord-0794973-qty33d4x
authors: Shin, Eunyong; Bae, Seongman; Jung, Jiwon; Song, Woo‐Jung; Kwon, Hyouk‐Soo; Kim, Hee‐Sung; Kim, Sung‐Han; Kim, Tae‐Bum; Cho, You Sook; Lee, Ji‐Hyang
title: Delayed local reactions after the first administration of the ChAdOx1 nCoV‐19 vaccine
date: 2021-06-26
journal: Allergy
DOI: 10.1111/all.14978
sha: c405b9298ac45bc2c6760553c97d1be23aa8e4c2
doc_id: 794973
cord_uid: qty33d4x

nan

To the editor Amid the COVID-19 pandemic, novel SARS-CoV-2 vaccines are expected to be the key to overcome this global health crisis. Since vaccination was initiated in December 2020, real-world data regarding adverse reactions and tolerability remain limited. 1 Herein, we report four cases of delayed local reaction that first occurred more and all subjects provided informed consent. Table 1 reactions, the recurrence rate was 50% and half of them were less severe than the initial reactions. 5 Considering the rarity and long time-to-onset (more than a week) interval of delayed local reaction, it might be regarded as irrelevant to vaccination or diagnosed as cellulitis, leading to unnecessary antibiotic treatment. This report might be the first to describe delayed local reaction resulting from ChAdOx1 nCoV-19 vaccination.

Given the speed of mass vaccination, clinicians need to be aware of potential adverse reactions and prepared to provide appropriate management.

TA B L E 1 Summarized cases of delayed local reactions after the first administration of ChAdOx1 nCoV-19 vaccine. F I G U R E 1 Delayed local reactions after the first administration of ChAdOx1 nCoV-19 vaccine, Images of skin lesions and their descriptions in each case

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US

Immunemediated adverse reactions to vaccines

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine